Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis

Ohio State University1 site in 1 country13 target enrollmentDecember 1, 2008

ConditionsLung Disease, Interstitial Idiopathic Pulmonary Fibrosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Lung Disease, Interstitial
Sponsor: Ohio State University
Enrollment: 13
Locations: 1
Primary Endpoint: Framework
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

Detailed Description

To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physiologic measures that follow patients through their course will allow the following proposed studies as well as future investigations to be efficiently carried out.

Registry

clinicaltrials.gov

Start Date

December 1, 2008

End Date

June 10, 2015

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Ohio State University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.